The phase III GOLD trial failed to show a significant improvement in OS with the addition of Olaparib to paclitaxel in patients with previously treated advanced gastric cancer in both the overall study population and in those with ATM deficiency (9). This evidence concerns the gene ATM and gastric cancer.